# Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery

> **NCT03446599** · PHASE2 · WITHDRAWN · sponsor: **Dartmouth-Hitchcock Medical Center**

## Conditions studied

- Vasoplegia
- Hypotension
- Coronary Artery Disease
- Cardiac Valve Disease

## Interventions

- **DRUG:** Hydroxocobalamin
- **DRUG:** Methylene Blue
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT03446599
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-11
- **Primary completion:** 2020-05
- **Final completion:** 2020-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03446599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03446599, "Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03446599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*